Your browser doesn't support javascript.
loading
Clinical meaningfulness of complete skin clearance in psoriasis.
Strober, Bruce; Papp, Kim A; Lebwohl, Mark; Reich, Kristian; Paul, Carle; Blauvelt, Andrew; Gordon, Kenneth B; Milmont, Cassandra E; Viswanathan, Hema N; Li, Joanne; Pinto, Lionel; Harrison, David J; Kricorian, Greg; Nirula, Ajay; Klekotka, Paul.
Affiliation
  • Strober B; University of Connecticut School of Medicine, Farmington, Connecticut. Electronic address: strober@uchc.edu.
  • Papp KA; Probity Medical Research, Waterloo, Ontario, Canada; K. Papp Medical Research, Waterloo, Ontario, Canada.
  • Lebwohl M; Icahn School of Medicine at Mount Sinai, New York, New York.
  • Reich K; Dermatologikum Hamburg, Hamburg, Germany.
  • Paul C; Paul Sabatier University, Toulouse, France.
  • Blauvelt A; Oregon Medical Research Center, Portland, Oregon.
  • Gordon KB; Northwestern University, Feinberg School of Medicine, Chicago, Illinois.
  • Milmont CE; Amgen Inc, Thousand Oaks, California.
  • Viswanathan HN; Amgen Inc, Thousand Oaks, California.
  • Li J; Amgen Inc, Thousand Oaks, California.
  • Pinto L; Amgen Inc, Thousand Oaks, California.
  • Harrison DJ; Amgen Inc, Thousand Oaks, California.
  • Kricorian G; Amgen Inc, Thousand Oaks, California.
  • Nirula A; Amgen Inc, Thousand Oaks, California.
  • Klekotka P; Amgen Inc, Thousand Oaks, California.
J Am Acad Dermatol ; 75(1): 77-82.e7, 2016 Jul.
Article in En | MEDLINE | ID: mdl-27206759
ABSTRACT

BACKGROUND:

New psoriasis therapies have increased the ability to achieve skin clearance. However, insufficient evidence exists on the impact of total skin clearance from the patient perspective.

OBJECTIVE:

We sought to determine if complete skin clearance is clinically meaningful compared with treatment responses without clearance.

METHODS:

Pooled data from 3 phase-III trials were used to compare results for patients with complete skin clearance (Psoriasis Area and Severity Index [PASI] 100 or static Physician Global Assessment score 0) with patients without complete skin clearance (PASI 75 to <100 or static Physician Global Assessment score 1) based on Psoriasis Symptom Inventory and Dermatology Life Quality Index.

RESULTS:

Percentages of patients with Psoriasis Symptom Inventory score 0 were 45% for those achieving PASI 100 and 8% for PASI 75 to <100 (P < .001). Respective percentages with Dermatology Life Quality Index score 0/1 were 80% and 55% (P < .001). PASI 100 resulted in incremental improvement over PASI 90 to <100 (incremental differences of 28% for Psoriasis Symptom Inventory score 0 and 18% for Dermatology Life Quality Index score 0). Similar results were observed for static Physician Global Assessment scores 0 versus 1.

CONCLUSIONS:

Complete skin clearance represents a clinically meaningful end point and outcome for patients, reflected in experiences of no psoriasis symptoms and no impairment on health-related quality of life.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Psoriasis / Quality of Life Type of study: Etiology_studies Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: J Am Acad Dermatol Year: 2016 Type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Psoriasis / Quality of Life Type of study: Etiology_studies Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: J Am Acad Dermatol Year: 2016 Type: Article